INCY - Incyte Corporation
67.67 0.00 (0.00%)
After hours: 4:56PM EST
| Previous Close | 65.60 |
| Open | 66.65 |
| Bid | 65.01 x 800 |
| Ask | 69.57 x 1200 |
| Day's Range | 66.65 - 68.60 |
| 52 Week Range | 58.33 - 102.63 |
| Volume | 1,091,903 |
| Avg. Volume | 1,497,295 |
| Market Cap | 14.401B |
| Beta (3Y Monthly) | 1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.51 |
| Earnings Date | Feb 13, 2019 - Feb 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.67 |
- Zacks•12 hours ago
Roche to Create Companion Diagnostic Test for Merck's Keytruda
Roche (RHHBY) signs collaboration agreement with Merck for developing a companion diagnostic test to identify patients for treatment with the latter's Keytruda.
- Motley Fool•2 days ago
Why MacroGenics Stock Is Getting Hammered Today
The cancer drug developer took a major hit, but here's why bargain hunters may want to take advantage of this opportunity.
Zacks•3 days ago5 Top Drug/Biotech Merger & Acquisition Targets for 2019
Here are five stocks that are attractive and most likely to be takeout targets in 2019.
- Zacks•6 days ago
Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger
Shire's (SHPG) pending acquisition by Takeda Pharmaceuticals for $62 billion gets approval from shareholders of both the companies.
- Zacks•8 days ago
Incyte (INCY) Announces Positive Data on Jakafi for GVHD
Incyte (INCY) announces positive data on lead drug Jakafi at the ASH meet for the indication of acute GVHD.
Markit•9 days agoSee what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCY
- ACCESSWIRE•9 days ago
Today's Research Reports on Trending Tickers: Incyte and Supernus Pharmaceuticals
NEW YORK, NY / ACCESSWIRE / December 4, 2018 / U.S. markets closed up on Monday as the U.S. and China came to an agreement of a 90-day trade war truce at the G-20 meeting in Argentina. The Dow Jones Industrial ...
- Business Wire•9 days ago
Results of REACH1 Study of Ruxolitinib (Jakafi®) for the Treatment of Acute Graft-Versus-Host Disease Demonstrate Rapid and Durable Patient Benefit
Incyte Corporation (INCY) announces updated results from its pivotal Phase 2 REACH1 study evaluating ruxolitinib (Jakafi®) in combination with corticosteroids as a treatment for patients with acute graft-versus-host disease (GVHD) who have had an inadequate response to corticosteroids. As previously announced, the study met its primary endpoint, demonstrating an overall response rate (ORR) of 55 percent (n=39/71) at Day 28, along with a best overall response rate (BORR) – patients achieving a response at any time point during the study – of 73 percent (n=52/71).
- Benzinga•10 days ago
The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs
Large-cap pharma stocks are seeing some upward momentum and are on track to finish the year with handsome gains. As the year draws to a close, it remains to be seen if these stocks can sustain the ongoing ...
- Zacks•13 days ago
Why Is Incyte (INCY) Up 1.5% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Markit•16 days agoSee what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCY
- Business Wire•16 days ago
Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer
Incyte (INCY) today announced the appointment of Dashyant Dhanak, Ph.D. as Executive Vice President and Chief Scientific Officer, effective December 10, 2018. Dr. Dhanak will succeed Dr. Reid Huber, who has been at Incyte since 2002 and is leaving the Company to pursue opportunities in the early-stage life sciences community. “Reid’s contributions to Incyte have been instrumental in its evolution from a start-up operation to the world-class discovery engine of today, and I thank him most sincerely for his commitment and critical thinking over the last 16 years,” said Hervé Hoppenot, Chief Executive Officer, Incyte.
- Simply Wall St.•19 days ago
A Look At The Intrinsic Value Of Incyte Corporation (NASDAQ:INCY)
I am going to run you through how I calculated the intrinsic value of Incyte Corporation (NASDAQ:INCY) by projecting its future cash flows and then discounting them to today’s value. Read More...
- Investor's Business Daily•21 days ago
This Highly Rated Pharma Giant Is More Than Just A Diabetes Player
Investors may know Eli Lilly for its diabetes treatments. But analysts say the Big Pharma giant is bound to get a boost from its migraine prevention and immunology drugs.
- Zacks•23 days ago
AstraZeneca's Imfinzi Fails in Lung Cancer Study, Stock Down
AstraZeneca (AZN) announced that Imfinzi as a monotherapy or in combination with tremelimumab failed to improve overall survival in first-line NSCLC. The combination had also failed to improve progression free survival last year.
- Zacks•27 days ago
Merck's Keytruda Improves Survival in Esophageal Cancer Study
Merck's (MRK) Keytruda meets primary endpoint of overall survival in a phase III study evaluating it for the second-line treatment of advanced esophageal cancer.
Markit•28 days agoSee what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCY
Markit•last monthSee what the IHS Markit Score report has to say about Incyte Corp.
Incyte Corp NASDAQ/NGS:INCY
- Business Wire•last month
Incyte to Present at Upcoming Investor Conference
Incyte Corporation announced today that it will present at Evercore ISI HEALTHCONx on Wednesday, November 28, 2018 at 3:30 pm EST in Boston.
Market Realist•last monthHow Wall Street Analysts View Exelixis
Exelixis (EXEL) reported net income of $126.6 million in the third quarter compared to $81.4 million in the third quarter of 2017. The company’s net income over the first nine months of this year amounted to $330.0 million compared to $115.7 million in the same period the prior year.
- GlobeNewswire•last month
Factors of Influence in 2018, Key Indicators and Opportunity within Molson Coors Brewing, Coca-Cola European Partners, Brinker International, Incyte, RPC, and Group 1 Automotive — New Research Emphasizes Economic Growth
NEW YORK, Nov. 05, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Motley Fool•last month
Incyte's Shares Have Taken a Beating in 2018 -- Here's Why
Here's what we can learn from the failure of Incyte's highly-touted cancer therapy.
- Motley Fool•last month
Scary Markets, Frightening Stocks, and How to Keep From Panicking
Here's what you need to know to keep your cool in terrifying times.
- Thomson Reuters StreetEvents•last month
Edited Transcript of INCY earnings conference call or presentation 30-Oct-18 12:00pm GMT
Q3 2018 Incyte Corp Earnings Call
